X hits on this document

181 views

0 shares

0 downloads

0 comments

31 / 61

Vasodilators in the Management of Acute Heart Failure Trial (VAMC)

Significant reduction in dyspnea score and PCWP with addition of NIseritide to standard therapy

Change in PCWP from baseline

Reduced dyspnea compared to standard therapy alone

Niseritide

Bolus 2 micr/kg

Nitroglycerine IV

489

Acute CHF

PCWP> 20mmHg

Randomized

Double-Blinded

Control

Effects at 3 hours

Outcomes

Primary End Point

Agents

Enrolled

Design

No good data to support adverse affects on renal function and niseritide

Retrospective analysis of VMAC showed potential for increased creatinin with increasing niseritide dose.

Document info
Document views181
Page views181
Page last viewedTue Jan 17 18:09:14 UTC 2017
Pages61
Paragraphs503
Words1542

Comments